USPTO Seeks Comments on Standard Trademark Board Paperwork
Published Date: 6/10/2026
Notice
Summary
The USPTO is asking for public feedback on continuing to collect info about Trademark Trial and Appeal Board (TTAB) actions, which affect businesses and individuals dealing with trademarks. This is a routine step to keep paperwork in check and won’t change fees or deadlines. You’ve got until August 10, 2026, to share your thoughts before the government gives the final thumbs-up.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 2 costs, 2 mixed.
Time and Labor Burden on Filers
The USPTO estimates 44,550 annual respondents and 76,000 annual responses for TTAB actions. The collection is estimated to require 1,016,891 total burden hours and an estimated hourly labor cost burden of $347,776,722 per year.
Filing Fees and Non-Hour Costs Remain
The notice lists existing TTAB filing fees and non-hour costs totaling an estimated $10,725,767 per year in filing fees and $767 in postage. Example fees include $600 per electronic Petition to Cancel, $600 per electronic Notice of Opposition, $200 per electronic Request for Extension in some cases, and $225 per electronic Ex Parte Appeal filing.
TTAB Information Collection Continued
The USPTO is asking to extend its existing information collection for Trademark Trial and Appeal Board (TTAB) actions (OMB Control No. 0651-0040). The agency seeks public comments by August 10, 2026, but this notice does not change existing fees or deadlines.
Electronic Filing Required (Mostly)
TTAB filings must be submitted electronically through the TTAB electronic filing system, though the USPTO allows paper submission by mail or hand delivery in certain circumstances.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14389, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Response to Office Action and Voluntary Amendment Forms
The USPTO is asking for public feedback on updating forms used to respond to trademark office actions and make voluntary changes. This affects anyone applying for or managing trademarks and could streamline the process without extra costs. Comments are open until September 15, 2026, so don’t miss your chance to weigh in!
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
2026-14240, References to Electronic Filing Systems in Rules of Practice in Filings Pursuant to the Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks
The USPTO is updating its rules to swap out specific electronic filing system names with more general terms for submitting international trademark applications under the Madrid Protocol. This change won’t affect how you file or any fees—it just makes the language clearer and easier to follow. The new rule kicks in on July 15, 2026, and applies to anyone filing international trademark paperwork from the U.S.
Previous / Next Documents
Previous: 2026-11574, Tris (Hydroxymethyl) Aminomethane and Tris (Hydroxymethyl) Aminomethane Hydrochloride (“Tris and Tris HCl”) From China; Determinations
The U.S. government is investigating whether imports of Tris and Tris HCl from China are hurting American businesses by being sold unfairly cheap or with government help. If confirmed, this could lead to new rules or tariffs to protect U.S. industries. Companies and consumers should watch for updates later this year that might affect prices and trade.
Next: 2026-11578, Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.